Reset filter
Nyckelord
ALL ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
    1. 1.1. Inkluderande/exkluderande
    1. 1.2. Anamnes
    1. 1.3. Kroppsundersökning
    1. 1.4. Poäng
    1. 1.5. Apparativ diagnostik
    1. 1.6. Laboratorium
    1. 1.7. Patologi och histologi
    1. 1.8. Upplysning/samtycke
    1. 1.9. Terapi
    1. 1.10. Operationsberättelse
    1. 1.11. Oönskad händelse
    1. 1.12. Uppföljning
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

104 Sökresultat.
Relevans Bedömning Nya först Gamla först

Eligibility DRKS00005163 NCT01207388 B-ALL - Eligibility

- 2021-09-27 - 1 Formulär, 2 Item-grupper, 14 Dataelement, 2 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01207388

Eligibility DRKS00003796 NCT01209286 B-ALL - Eligibility

- 2021-09-27 - 1 Formulär, 2 Item-grupper, 15 Dataelement, 2 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01209286

Eligibility Leukemia, Lymphocytic NCT00313079

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 35 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00313079

Anamnese und klinische Untersuchung OPAL-Studie DRKS00004421 NCT01619124 ALL - Anamnese und klinische Untersuchung OPAL-Studie

- 2021-09-20 - 1 Formulär, 13 Item-grupper, 72 Dataelement, 2 Språk
Item-grupper: Allgemeine Angaben, Tägliche Aktivitäten, Gehen, Gelenkinspektion, Bewegungsumfang (in °) Hüftgelenk, Bewegungsumfang (in °) Kniegelenk, Bewegungsumfang (in °) Sprunggelenk, Muskelbefund Oberschenkel, Muskelbefund Unterschenkel, Therapiekomplikationen, Begleitmedikation, Spez. Intervention gegen Osteonekrosen, Bemerkungen
Osteonekrosen bei pädiatrischen Patienten mit ALL

On-Study - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Previously Untreated Patients - 2019397v3.0 - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Previously Untreated Patients

- 2021-09-20 - 1 Formulär, 4 Item-grupper, 34 Dataelement, 1 Språk
Item-grupper: CRF Header, ALL: Form Administration, ALL: Disease Description, Comments
Acute Lymphocytic Leukemia (ALL) - On-Study Form - Previously Untreated Patients Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B24E435-7CDC-500C-E044-0003BA3F9857

On-Study - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Relapse/Refractory Treatment - 2019356v3.0 - Acute Lymphocytic Leukemia (ALL) - On-Study Form - Relapse/Refractory Treatment

- 2021-09-20 - 1 Formulär, 4 Item-grupper, 37 Dataelement, 1 Språk
Item-grupper: CRF Header, ALL: Form Administration, ALL: Disease Description, Comments
Acute Lymphocytic Leukemia (ALL) - On-Study Form - Relapse/Refractory Treatment Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=1B24EE5B-237E-50D5-E044-0003BA3F9857

Eligibility NCT01195480 Acute Lymphoblastic Leukemia - Eligibility

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 28 Dataelement, 2 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01195480

Eligibility Acute Lymphoblastic Leukemia NCT01685411

- 2021-09-17 - 1 Formulär, 2 Item-grupper, 17 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Busulfan and Cyclophosphamide Followed By ALLO BMT; ODM derived from: https://clinicaltrials.gov/show/NCT01685411

Eligibility Acute Lymphoblastic Leukemia NCT00957320

- 2021-09-17 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT00957320

Eligibility Acute Lymphoblastic Leukemia NCT02186860

- 2021-09-17 - 1 Formulär, 2 Item-grupper, 20 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT02186860

Eligibility Leukemia NCT00452439

- 2021-09-02 - 1 Formulär, 2 Item-grupper, 13 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
A Study of Actonel for the Prevention of Bone Loss; ODM derived from: https://clinicaltrials.gov/show/NCT00452439

Maintenance therapy R2 AIEOP-BFM ALL 2009 DRKS00003772 NCT01117441 - Maintenance therapy R2 AIEOP-BFM ALL 2009 NCT01117441

- 2021-03-15 - 1 Formulär, 3 Item-grupper, 21 Dataelement, 1 Språk
Item-grupper: Patient Information, Examinations, Identification and Signature
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia. Phase 3 Study. Documentation part. Clinical Trial Number: NCT01117441.

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial